Skip to main content
SpringerLink
Log in

Monoclonal Antibodies in Cancer

  • Chapter
  • First Online:
Pharmaceutical Biotechnology

Abstract

Cancer is the second leading cause of death in the United States with one of every four deaths attributable to cancer (Jemal et al. 2006). The first references to cancer date back to Egyptian papyrus circa 1600 BC. The introduction of nitrogen mustards in the 1940s can be considered the origin of modern, systemic antineoplastic therapies (Papac 2001). Rapid improvements in the understanding of cancer biology, medicinal chemistry, and biopharmaceutical technology have provided rationally designed drugs exploiting differences in normal and malignant cells. Monoclonal antibodies (MABs) bind to a specific epitope. This allows for a targeting approach for the development of effective anticancer compounds with relatively less and/or nonoverlapping toxicity compared to other cytotoxic drugs used to treat cancer. In cancer treatment, MABs have been developed that exert a wide array of pharmacologic effects. This chapter focuses on FDA-approved MABs for the treatment of cancer and cancer-related symptoms. Antibodies are organized based on their target. Table 17.1 summarizes the current FDA-approved MABs for cancer indications, year of approval, target, and the indications that are discussed within the chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29(3):264–271

    PubMed  CAS  Google Scholar 

  • Ansell SM (2011) Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs 20(1):99–105

    PubMed  CAS  Google Scholar 

  • Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

    PubMed  CAS  Google Scholar 

  • Baselga J, Tripathy D, Mendelsohn J et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26(4 Suppl 12):78–83

    PubMed  CAS  Google Scholar 

  • Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119

    PubMed  CAS  Google Scholar 

  • Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578

    PubMed  CAS  Google Scholar 

  • Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12(5):567–580

    PubMed  CAS  Google Scholar 

  • Clark AJ, Butowski NA, Chang SM et al (2011) Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 114(6):1609–1616

    PubMed  Google Scholar 

  • Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18(1):7–15

    PubMed  CAS  Google Scholar 

  • Coiffier B (2002) Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 29(1 Suppl 2):30–35

    PubMed  CAS  Google Scholar 

  • Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242

    PubMed  CAS  Google Scholar 

  • Coleman RE (2004a) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14–27

    PubMed  CAS  Google Scholar 

  • Coleman RE (2004b) The role of bisphosphonates in breast cancer. Breast 13(Suppl 1):S19–S28

    PubMed  Google Scholar 

  • Cortes J, Fumoleau P, Bianchi GV et al (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(14):1594–1600

    PubMed  CAS  Google Scholar 

  • Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345

    PubMed  CAS  Google Scholar 

  • Delbaldo C, Pierga JY, Dieras V et al (2005) Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer 41(12):1739–1745

    PubMed  CAS  Google Scholar 

  • Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633–659

    PubMed  CAS  Google Scholar 

  • Dirks NL, Nolting A, Kovar A et al (2008) Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 48(3):267–278

    PubMed  CAS  Google Scholar 

  • Dowell JA, Korth-Bradley J, Liu H et al (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41(11):1206–1214

    PubMed  CAS  Google Scholar 

  • Faderl S, Thomas DA, O’Brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413–3415

    PubMed  CAS  Google Scholar 

  • Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581–611

    PubMed  CAS  Google Scholar 

  • Foyil KV, Kennedy DA, Grove LE et al (2012) Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leuk Lymphoma 53(3):506–507

    PubMed  CAS  Google Scholar 

  • Frampton JE, Wagstaff AJ (2003) Alemtuzumab. Drugs 63(12):1229–1243; discussion 1245–1226

    PubMed  CAS  Google Scholar 

  • Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458–1465

    PubMed  CAS  Google Scholar 

  • Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740

    PubMed  CAS  Google Scholar 

  • Furtado M, Rule S (2012) Emerging pharmacotherapy for relapsed or refractory Hodgkin’s lymphoma: focus on brentuximab vedotin. Clin Med Insights Oncol 6:31–39

    PubMed  CAS  Google Scholar 

  • Gibiansky L, Sutjandra L, Doshi S et al (2012) Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 51(4):247–260

    PubMed  CAS  Google Scholar 

  • Giles F, Estey E, O’Brien S (2003) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98(10):2095–2104

    PubMed  CAS  Google Scholar 

  • Gopal AK, Ramchandren R, O’Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplant. Blood 120(3):150–158

    Google Scholar 

  • Guarneri V, Frassoldati A, Bruzzi P et al (2008) Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 8(5):453–456

    PubMed  CAS  Google Scholar 

  • Haddley K (2012) Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin’s lymphoma. Drugs Today (Barc) 48(4):259–270

    CAS  Google Scholar 

  • Hagenbeek A, Lewington V (2005) Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 16(5):786–792

    PubMed  CAS  Google Scholar 

  • Hanaizi Z, van Zwieten-Boot B, Calvo G et al (2012) The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 48(2):237–242

    PubMed  CAS  Google Scholar 

  • Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132

    PubMed  CAS  Google Scholar 

  • Hochster H, Weller E, Gascoyne RD et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 27(10):1607–1614

    PubMed  CAS  Google Scholar 

  • Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    PubMed  CAS  Google Scholar 

  • Huang BT, Zeng QC, Yu J et al (2012) How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol 138(1):125–132

    PubMed  CAS  Google Scholar 

  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62

    PubMed  CAS  Google Scholar 

  • Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130

    PubMed  Google Scholar 

  • Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184–2191

    PubMed  CAS  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765

    PubMed  CAS  Google Scholar 

  • Keating GM (2012) Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 72(3):353–360

    PubMed  CAS  Google Scholar 

  • Keating M, Hallek M (2002) Alemtuzumab, the first monoclonal antibody (MAB) directed against CD52. Med Oncol 19(Suppl):S1–S2

    PubMed  Google Scholar 

  • Kennedy B, Hillmen P (2002) Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL. Med Oncol 19(Suppl):S49–S55

    PubMed  Google Scholar 

  • Korth-Bradley JM, Dowell JA, King SP et al (2001) Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy 21(10):1175–1180

    PubMed  CAS  Google Scholar 

  • Koutcher LD, Wolden S, Lee N (2009) Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol 32(5):472–476

    PubMed  CAS  Google Scholar 

  • Lenihan DJ, Alencar AJ, Yang D et al (2004) Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104(3):655–658

    PubMed  CAS  Google Scholar 

  • Leyland-Jones B, Gelmon K, Ayoub JP et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21(21):3965–3971

    PubMed  CAS  Google Scholar 

  • Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958–6962

    PubMed  CAS  Google Scholar 

  • Liu NS, O’Brien S (2004) Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Med Oncol 21(4):297–304

    PubMed  Google Scholar 

  • Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62(5):779–786

    PubMed  CAS  Google Scholar 

  • Lundin J, Kimby E, Bjorkholm M et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100(3):768–773

    PubMed  CAS  Google Scholar 

  • Lundin J, Kennedy B, Dearden C et al (2005) No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 105(10):4148–4149

    PubMed  CAS  Google Scholar 

  • Maloney DG, Liles TM, Czerwinski DK et al (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8):2457–2466

    PubMed  CAS  Google Scholar 

  • Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90(6):2188–2195

    PubMed  CAS  Google Scholar 

  • McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825–2833

    PubMed  CAS  Google Scholar 

  • Minich SS (2012) Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother 46(3):377–383

    PubMed  Google Scholar 

  • Montagna M, Montillo M, Avanzini MA et al (2011) Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica 96(6):932–936

    PubMed  CAS  Google Scholar 

  • Montillo M, Tedeschi A, Miqueleiz S et al (2006) Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24(15):2337–2342

    PubMed  CAS  Google Scholar 

  • Nabhan C, Patton D, Gordon LI et al (2004) A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 45(11):2269–2273

    PubMed  CAS  Google Scholar 

  • Ng CM, Lum BL, Gimenez V et al (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23(6):1275–1284

    PubMed  CAS  Google Scholar 

  • O’Brien S, Albitar M, Giles FJ (2005) Monoclonal antibodies in the treatment of leukemia. Curr Mol Med 5(7):663–675

    PubMed  Google Scholar 

  • Oki Y, Younes A (2012) Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 12(5):623–632

    PubMed  CAS  Google Scholar 

  • Osterborg A, Mellstedt H, Keating M (2002) Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 19(Suppl):S21–S26

    PubMed  Google Scholar 

  • Papac RJ (2001) Origins of cancer therapy. Yale J Biol Med 74(6):391–398

    PubMed  CAS  Google Scholar 

  • Pawson R, Dyer MJ, Barge R et al (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15(7):2667–2672

    PubMed  CAS  Google Scholar 

  • Pinto C, Barone CA, Girolomoni G et al (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16(2):228–238

    PubMed  Google Scholar 

  • Planchard D (2011) Bevacizumab in non-small-cell lung cancer: a review. Expert Rev Anticancer Ther 11(8):1163–1179

    PubMed  CAS  Google Scholar 

  • Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 63(8):803–843

    PubMed  CAS  Google Scholar 

  • Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30(18):2190–2196

    PubMed  CAS  Google Scholar 

  • Rai KR, Freter CE, Mercier RJ et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20(18):3891–3897

    PubMed  CAS  Google Scholar 

  • Reck M, Barlesi F, Crino L et al (2012) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23(5):1111–1120

    PubMed  CAS  Google Scholar 

  • Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526

    PubMed  CAS  Google Scholar 

  • Romas E (2009) Clinical applications of RANK-ligand inhibition. Intern Med J 39(2):110–116

    PubMed  CAS  Google Scholar 

  • Rowinsky EK, Schwartz GH, Gollob JA et al (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22(15):3003–3015

    PubMed  CAS  Google Scholar 

  • Saif MW, Cohenuram M (2006) Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 6(2):118–124

    PubMed  CAS  Google Scholar 

  • Salar A, Casao D, Cervera M et al (2006) Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77(4):338–340

    PubMed  CAS  Google Scholar 

  • Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550

    PubMed  CAS  Google Scholar 

  • Sehn LH, Donaldson J, Filewich A et al (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171–4173

    PubMed  CAS  Google Scholar 

  • Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649

    PubMed  CAS  Google Scholar 

  • Shirao K, Yoshino T, Boku N et al (2009) A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer Chemother Pharmacol 64(3):557–564

    PubMed  CAS  Google Scholar 

  • Sievers EL, Appelbaum FR, Spielberger RT et al (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93(11):3678–3684

    PubMed  CAS  Google Scholar 

  • Skarbnik AP, Smith MR (2012) Brentuximab vedotin in anaplastic large cell lymphoma. Expert Opin Biol Ther 12(5):633–639

    PubMed  CAS  Google Scholar 

  • Specenier P (2012) Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12(1):9–18

    PubMed  CAS  Google Scholar 

  • Specenier P, Vermorken JB (2011) Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 11(4):511–524

    PubMed  CAS  Google Scholar 

  • Stilgenbauer S, Zenz T, Winkler D et al (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27(24):3994–4001

    PubMed  CAS  Google Scholar 

  • Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139

    PubMed  CAS  Google Scholar 

  • Studer G, Brown M, Salgueiro EB et al (2011) Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT. Int J Radiat Oncol Biol Phys 81(1):110–117

    PubMed  Google Scholar 

  • Swain SM, Kim SB, Cortés J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results form a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 14:461–471

    PubMed  CAS  Google Scholar 

  • Thompson CB, Allison JP (1997) The emerging role of CTLA-4 as an immune attenuator. Immunity 7(4):445–450

    PubMed  CAS  Google Scholar 

  • Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29(2):149–156

    PubMed  CAS  Google Scholar 

  • van Der Velden VH, te Marvelde JG, Hoogeveen PG et al (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10):3197–3204

    Google Scholar 

  • Wagner-Johnston ND, Bartlett NL, Cashen A et al (2012) Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 53(11):2283–2286

    PubMed  CAS  Google Scholar 

  • Wahl AF, Klussman K, Thompson JD et al (2002) The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 62(13):3736–3742

    PubMed  CAS  Google Scholar 

  • Waterhouse P, Penninger JM, Timms E et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985–988

    PubMed  CAS  Google Scholar 

  • Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507

    PubMed  CAS  Google Scholar 

  • Witzig TE, Flinn IW, Gordon LI et al (2002a) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20(15):3262–3269

    PubMed  CAS  Google Scholar 

  • Witzig TE, Gordon LI, Cabanillas F et al (2002b) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463

    PubMed  CAS  Google Scholar 

  • Wood AM (2001) Rituximab: an innovative therapy for non-Hodgkin’s lymphoma. Am J Health Syst Pharm 58(3):215–229, quiz 230–212

    PubMed  CAS  Google Scholar 

  • Yamamoto N, Yamada Y, Fujiwara Y et al (2009) Phase I and pharmacokinetic study of HER2-targeted rhuMAB 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 39(4):260–266

    PubMed  Google Scholar 

  • Yang XD, Jia XC, Corvalan JR et al (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38(1):17–23

    PubMed  CAS  Google Scholar 

  • Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812–1821

    PubMed  CAS  Google Scholar 

  • Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA

    Amy Grimsley PharmD

  2. Department of Pharmaceutical Services, Emory University Hospital/Winship Cancer Institute, 1365 Clifton RD, Building C, Atlanta, 30322, GA, USA

    Katherine S. Shah PharmD & Trevor McKibbin PharmD, MS, BCPS

Authors
  1. Amy Grimsley PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine S. Shah PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Trevor McKibbin PharmD, MS, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor McKibbin PharmD, MS, BCPS .

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, Utrecht University, Utrecht, Utrecht, The Netherlands

    Daan J. A. Crommelin

  2. Department of Pharmaceutical Sciences and Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada

    Robert D. Sindelar

  3. Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, College of Pharmacy, Memphis, Tennessee, USA

    Bernd Meibohm

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Grimsley, A., Shah, K.S., McKibbin, T. (2013). Monoclonal Antibodies in Cancer. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6486-0_17

Download citation

Publish with us

Policies and ethics

Search

Navigation